GlassScriptPhysician profile
Anet Proenza
NPI 1558040949
$6,973.60
in general payments reported to CMS, 2019-2025
30 companies · $3,234 in 2025
The $3,234 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $869 · 2024: $2,870 · 2025: $3,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,875 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,875.26 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,732.41 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $975.04 | 2023-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $506.79 | 2023-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $479.24 | 2023-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $449.81 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $437.86 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $381.71 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $290.40 | 2024-2025 | |
| Baxter Healthcare | $271.31 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $248.95 | 2023-2025 | Acthar |
| United Therapeutics Corporation | $201.30 | 2023-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $191.97 | 2025 | Ohtuvayre |
| Amgen INC. | $179.56 | 2023-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.52 | 2023-2025 | Ofev, Jascayd |
| Shield Therapeutics INC | $61.32 | 2023-2024 | Accrufer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.29 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $38.57 | 2024 | Horizant |
| Pfizer INC. | $35.75 | 2023 | |
| Merck Sharp & Dohme LLC | $33.11 | 2023 | |
| Alk-Abello, INC | $32.64 | 2023 | Grastek, Ragwitek, Odactra |
| Electromed, INC. | $30.84 | 2023-2024 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $28.58 | 2024 | |
| Boston Scientific Corporation | $26.06 | 2023 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $25.99 | 2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $25.50 | 2024 | Uptravi, Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $21.11 | 2025 | Lumryz |
| Optinose US, INC. | $19.73 | 2024 | |
| Inogen, INC. | $19.64 | 2025 | |
| Liquidia Technologies, INC. | $17.32 | 2025 | Yutrepia |
| Phadia US INC. | $15.28 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anet Proenza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.